D
espite much progress in atherosclerosis research, stroke continues to be the third most common cause of death in the United States. Atheroembolic disease originating in the extracranial carotid artery accounts for approximately 60% of all strokes. 1 Carotid endarterectomy (CEA) has clearly been shown to be effective in reducing the risk of stroke in selected patients with carotid stenosis. Specifically, several prospective, randomized trials have shown a significant reduction in the risk of stroke when CEA was compared with medical therapy in patients with high-grade asymptomatic carotid stenoses as well as moderate to high-grade symptomatic stenoses. [2] [3] [4] In several large reviews, the combined risk of postoperative stroke or death in patients undergoing CEA has been shown to be approximately 3% for previously asymptomatic patients 5, 6 and 5% to 6% for those with symptomatic stenoses, 6, 7 with even lower reported rates from several high-volume institutions. 8, 9 Recently, carotid angioplasty with stenting (CAS) has emerged as an alternative treatment of carotid stenosis. The purported advantages of this procedure include its less invasive nature and ability to treat anatomically difficult-to-access lesions. Some have also suggested CAS to be potentially safer, with less anesthetic risks and increased cost-effectiveness compared with CEA, the current gold standard. Early results with CAS have been quite variable, reflecting the heterogeneous patient populations studied. However, a recent multicenter prospective, randomized trial comparing CAS and CEA presented in abstract form at the 2001 AHA International Stroke Conference revealed a combined 1-year mortality and stroke rate of 12.1% for CAS versus 3.6% for CEA, leaving in question which subset of patients would be most suitable for CAS. 10 This has led to the notion that CAS be reserved as an alternative treatment of surgical patients at "high risk" for postoperative complications. Attempts to define this "high-risk" population have been made by several authors with variable agreement as to which patient factors are most predictive of poor outcome. Nevertheless, enrollment into clinical trials comparing CAS and CEA, often based on different criteria, is currently in progress.
Given these uncertainties in defining groups of surgical patients at high risk for postoperative complications, we tested the hypothesis that "high-risk" patients can undergo CEA without associated increased incidence of stroke, TIA, or death.
MATERIALS AND METHODS
During a 5-year period from 1996 to 2001, all patients who had a CEA performed at a single institution had their medical records reviewed for demographics, medical history, and hospital course. Specifically, preadmission comorbidities, medication profiles, presenting neurologic symptoms, operative details, as well as the nature of any postoperative complications were recorded. Patients' presenting symptoms were classified as asymptomatic, transient ischemic attack (TIA), and stroke. Gathered data was entered into a computerized database, and the study design was approved by the Institutional Review Board (#2002-0027).
Patients were divided into "high-risk" and "low-risk" groups based on the presence of certain risk factors. "Highrisk" patients were defined as those with at least 1 of the following risk factors 6, 8, 11 : myocardial infarction (MI) or exacerbation of congestive heart failure (CHF) within 4 weeks before CEA; unstable angina; steroid-dependent chronic obstructive pulmonary disease (COPD); prior ipsilateral CEA, neck dissection or irradiation; high carotid bifurcation, as noted angiographically (at the C2 level or higher) or intraoperatively by the surgeon; and those undergoing combined cardiac-carotid procedures. Myocardial infarction was defined as an event resulting in elevation of cardiac enzymes or electrocardiographic (EKG) changes. High-risk patients with CHF included those with an ejection fraction of less than 30% or New York Heart Association class III or IV symptoms requiring hospitalization. Mild CHF exacerbations treated clinically in an outpatient setting were not counted. Ejection fraction was documented in the medical record by echocardiography, a nuclear medicine study, or by direct ventriculography at the time of cardiac catheterization.
"Poor outcome" was defined by the primary postoperative composite end points of stroke, TIA, or death within 30 days. These events were recognized based on descriptions in the computerized medical record by the surgeon, internist, neurologist, and/or rehabilitative team, as well as the results of radiographic tests (eg, head computed tomography or brain magnetic resonance imaging). The incidence of these outcomes was calculated as a percentage of the total number of procedures among the entire group as well as for the high-risk and low-risk subgroups. Stroke was defined as the presence of a new neurologic deficit for greater than 24 hours, whereas TIA represented a transient deficit present for 24 hours or less. The incidence of MI within the first 30 days after CEA was similarly calculated and based on documentation within the medical record of cardiac enzyme elevation or EKG changes. Cardiac enzyme levels were assessed only in response to appropriate patient signs or symptoms (eg, chest pain, hypoxia, arrhythmia) and not obtained routinely in the postoperative setting.
Univariate analysis by chi-squared method and multivariate logistic analysis were used to assess the relationship between risk factors and a poor outcome. Kaplan-Meier analysis was performed, and survival curves for both the high-risk and low-risk groups were constructed. Statistical analysis was performed with SAS software (version 8.0; SPSS, Chicago, IL). A P value of less than 0.05 was considered significant.
RESULTS
From 1996 to 2001, 429 patients underwent 499 carotid endarterectomies. Patient characteristics are summarized in Table 1 . The mean patient age was 69 Ϯ 9 years, with the majority of CEAs performed in males (59%). Sixty-nine CEAs (14%) were performed after conventional cerebral angiography, 31 (6%) after magnetic resonance angiography (MRA), whereas the remaining 399 (80%) were performed based solely on the results of duplex carotid ultrasonography obtained through our ICAVL-accredited vascular laboratory. Generally, asymptomatic patients with greater than 80% stenosis and symptomatic patients with greater than 60% stenosis by duplex ultrasonography were considered candidates for CEA. Endarterectomy based on duplex ultrasonography has been our standard practice, because direct correlation of duplex with arteriography has been well established at our vascular laboratory since the 1980s. In terms of operative technique (Table 2) , 461 (92%) were performed under regional anesthesia with the remaining 38 (8%) under general anesthesia. Fifty-nine CEAs (12%) required the use of a shunt intraoperatively. Patch closure of the carotid artery was performed as a part of 121 (24%) CEAs. None of these patients required redo CEA for recurrent stenosis. However, of the 378 CEAs performed without patch closure, 9 (2.4%) developed recurrent stenoses requiring redo CEA (P ϭ 0.19). It should be noted that no specific algorithm was used to determine closure technique, although the technique of choice among our surgeons has changed over this time period. Currently, all surgeons at our institution use patch closure routinely based on results of prospective trials demonstrating reduced stroke and restenosis rates compared with primary closure.
One hundred ninety-seven CEAs (39%) were performed for symptomatic disease as defined by NASCET criteria, 3, 4 whereas the remaining 302 (61%) were asymptomatic. Of the symptomatic patients, 144 (73%) were performed for TIA, 39 (20%) for stroke, and 14 (7%) in patients with a history of both TIA and stroke. In terms of the nature of symptoms, 65 (33%) had a history of amaurosis fugax, 120 (61%) had cerebral hemispheric symptoms, whereas 12 (6%) had both. Interestingly, 91 CEAs (46%) were performed within 6 weeks of symptoms. Eighty-four (17%) CEAs were considered high risk based on the presence of at least 1 of the risk factors listed here. Outcomes as a whole as well as in the asymptomatic and symptomatic subgroups are summarized in Tables 3 and 4 . By log-rank analysis, 12-month survival was significantly worse in the high-risk group as compared with the low-risk (91% vs. 96%, P ϭ 0.03; Fig. 1 ).
The overall stroke-death among all patients was 2.8%. A total of 11 postoperative strokes (2.2%), 7 TIAs (1.4%), and 3 deaths (0.6%) occurred within 30 days after surgery. Of those with strokes, 9 of 11 (82%) occurred within 4 days of operation, whereas the remaining 2 occurred on postoperative days 8 and 30. Two of these strokes presented as focal neurologic deficits intraoperatively before carotid artery clamping, with symptoms persisting for 48 hours or greater. These likely resulted from dissection adjacent to the carotid artery leading to dislodgement of atheromatous debris into the cerebral circulation. In terms of those with TIAs, 4 of 7 occurred within the first 24 hours after surgery, whereas the remaining 3 had more variable presentations up to 1 month postoperatively. The 3 patient deaths were related to sepsis several weeks after CEA, a fatal arrhythmia after discharge, and anoxic brain injury after loss of the airway subsequent to combined CEA and resection of a mandibular cancer.
There was no difference in poor outcome rates between high-and low-risk patients (4.8% vs. 4.1%, P ϭ 0.77; Table  3 ). When these risk factors were assessed by univariate and multivariate analysis, those with recent MI were at higher risk for poor outcome (odds ratio ͓OR͔, 13.3; 95% confidence interval ͓CI͔ 2.2-82.0; P ϭ 0.03). Specifically, of the 7 patients with recent MI, 1 sustained a postoperative stroke related to carotid artery occlusion, whereas the other sustained a fatal cardiac arrest with ventricular fibrillation at home after uneventful sequential CEA and coronary artery bypass grafting 2 weeks previously. Univariate and multivariate analysis also revealed that a history of contralateral stroke or TIA conferred an increased risk of poor outcome (OR, 3.0; 95% CI, 1.1-8.4; P ϭ 0.02), with 7 of 74 patients sustaining a perioperative stroke or TIA. In fact, only 23% (17 of 74) of patients with a history of contralateral CVA or TIA had a contralateral occlusion, whereas 1 additional patient had a high-grade contralateral stenosis. The remainder had mild to moderate disease.
Use of preoperative angiotensin-converting enzyme (ACE) inhibitors was associated with reduced risk of composite poor outcome (OR, 0.36; 95% CI, 0.11-1.0; P ϭ 0.05), as was the presence of hyperlipidemia (OR, 0.33; 95% CI, 0.13-0.87; P ϭ 0.03). It should be noted that of the 333 patients with a history of hyperlipidemia (defined as a total cholesterol of greater than 240 mg/dL or triglycerides greater than 200 mg/dL according to University of Michigan laboratories), 248 (74.5%) were on statin therapy. However, among all patients, there was no difference in risk of poor outcome when those on statins were compared with those not on statins (4.4% vs. 4.0%; P ϭ not significant). It should be noted that use of a statin was assessed separately and not assumed to treat a specific level of hypercholesterolemia as this was physician-specific. There were a total of 5 myocardial infarctions (1%), which occurred within 30 days of CEA. Two of these were among high-risk patients (2 of 84), whereas the remaining 3 were among low-risk patients (3 of 415). Although the incidence of post-CEA MI was higher in high-risk patients, this difference was not statistically significant (2.4% vs. 0.7%, P ϭ not significant).
DISCUSSION
Carotid endarterectomy has been established as the gold standard in the treatment of both symptomatic and asymptomatic carotid stenosis based on the results of several prospective, randomized, controlled trials. [2] [3] [4] Recently, CAS has emerged as an alternative treatment of patients considered at increased risk for perioperative complications. However, defining which patients actually fall into this high-risk group has been difficult, and some have elected to include patients in CAS clinical trials that were deemed ineligible by NASCET or ACAS criteria based on medical comorbidities or a history of previous ipsilateral CEA. To better define which patients might benefit from CAS, we retrospectively reviewed our institutional experience with carotid endarterectomy over the past 5 years. The patients were categorized as high risk versus low risk based on the presence of certain risk factors as promulgated by combined interventional radiology, vascular surgery, and cardiology experts. 6, 8, 11 In our analysis, we found that high-risk patients as a whole had no greater risk of 30-day poor outcome than the low-risk group. Not unexpectedly, 12-month survival was significantly worse in the high-risk group as compared with the low-risk group (91% vs. 96%), underscoring the severity of medical comorbidities shared among the high-risk patients; these curves merged beyond 24 months. Those patients with a history of recent CHF, unstable angina, steroid-or oxygen-dependent COPD, prior ipsilateral CEA, prior neck dissection or irradiation, high bifurcation, and combined cardiac-carotid procedures did not appear to be at increased risk for stroke, TIA, or death. Although the numbers of patients within each group are small, our results underscore those of others. Both Jordan et al 8 and Kucey et al 12 have similarly found no increased risk of stroke or death in patients with these "physiological" risk factors. In addition, Jordan et al 8 found no worse outcome among those with combined cardiac-carotid revascularization, recurrent disease, or other anatomic limitations (ie, high bifurcation). Similarly, the safety of reoperative CEA has also been demonstrated recently by Hill et al 13 in which the redo CEA group had no postoperative deaths, strokes, or permanent cranial nerve deficits. Likewise, Friedell et al 14 demonstrated that CEA could be performed safely in patients after neck irradiation and radical neck dissection with low incidence of perioperative complications or morbidity. Our results, in corroboration with those of others, suggest that CEA can be performed safely in patients previously considered "high risk" and should remain the standard of care.
Although the subset was small, our data suggest that patients with recent myocardial infarction may benefit from CAS because those with myocardial infarction within the 4 weeks before surgery had a significantly greater risk of poor outcome (29% vs. 3.9%). This result was not surprising as operative risks in patients with recent MI have been associated with increased perioperative risks after other noncardiac surgery. 15 However, their worse outcome may also be indicative of overall more "unstable" atherosclerotic disease and plaque pathology, because 43% (3 of 7) of these patients were also symptomatic from a cerebrovascular standpoint preoperatively. Gross et al 22 points out that stenting may be ideally suited for this high-risk group, because arterial access to the coronary circulation for percutaneous transluminal coronary angiography (PTCA) is immediately available, should acute myocardial ischemia occur. Furthermore, CAS before elective PTCA may reduce the risk of stroke should a coronary artery bypass grafting be required to salvage failed PTCA. 16 Those with a history of contralateral stroke or TIA also conferred an increased risk of poor outcome (9.5% vs. 3.3%). The reason for this difference is not completely clear, because not all patients with a history of contralateral CVA or TIA had significant contralateral internal carotid artery (ICA) stenosis. This risk factor may simply be a marker for more diffuse cerebrovascular disease, both intracranial and extracranial, increasing the risk of stroke or TIA with carotid clamping or during states of perioperative hypotension. It may also reflect cerebral watershed areas that are underperfused during clamping. Interestingly, several authors have reported on the apparent safety of CEA in the setting of contralateral ICA occlusion or high-grade stenosis, often taking advantage of regional anesthesia and selective intraoperative shunting (as performed at our institution), allowing a real-time neuro examination. 17, 18 Indeed, of the 74 patients with a history of contralateral CVA or TIA, 12 (16.2%) required a shunt, whereas of the remaining 425 patients, 47 (11.1%) required a shunt. Despite this, given the near 10% risk of poor outcome in this group, carotid angioplasty and stenting in this circumstance may prove to be at least equivalent to CEA and might be considered as alternative treatment.
Preoperative ACE inhibitor use was associated with a significant reduction in the risk of stroke, TIA, or death (2.0% vs. 5.7%) after CEA. Interestingly, only 202 of 499 CEAs were performed in patients on ACE inhibitors. The cardioprotective effects of ACE inhibitors are well recognized, and these medications are recommended for patients with general atherosclerosis. The reduced risk in patients undergoing CEA may reflect this cardioprotective effect in the perioperative setting. Alternatively, some ACE inhibitors such as fosinopril have been shown to reduce platelet aggregation, suggesting an alternative explanation for the observed stroke/TIA risk reduction after CEA. 19 Similarly, the reduced risk of poor outcome in patients with hyperlipidemia may reflect the widespread use of statin agents in this population, although for unclear reasons, their use did not appear to be protective in our study. Through multiple mechanisms, these agents have been shown to decrease plaque "vulnerability," improve endothelial function, reduce platelet thrombus deposition, and normalize hypercoagulability and fibrinolytic activity. 20 The low overall rate of postoperative myocardial infarction (1%) may reflect this widespread use of ACE inhibitors and statin agents, as well as the universal perioperative use of aspirin (or often other antiplatelet therapy) among our patients. This may also be reflective of the liberal use of regional anesthesia at our institution (92%), believed by many to carry substantial hemodynamic benefits compared with general anesthesia. 21 Certainly, it will be important to consider the anesthesia used in surgical patients when interpreting the results, and conclusions of ongoing and recently completed clinical trials comparing CAS and surgery, as the resultant cardiac morbidity among surgical patients, plays heavily into their outcome.
Indeed, the results of the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) 22 trial, released in abstract form in November 2002, highlight this issue. In this prospective, randomized trial of CAS versus CEA in 307 high-risk patients, there were no statistically significant differences in stroke, death, or MI rates between the groups. However, when taken together, the CAS stroke-death-MI rate was 5.8% compared with 12.5% in the CEA group (P ϭ 0.047). Most of this difference was accounted for by non-Q-wave MIs detected on routine perioperative troponin I assessments. This high 7.3% incidence of MI in the surgical arm has not been seen by other groups. In fact, a recent review by Mozes et al 23 of 776 CEAs only documented a 3.1% NQWMI rate in the high-risk "SAPPHIRE-eligible" group. Because the details of the SAPPHIRE methods are not yet available, it is difficult to assess what difference such factors as anesthetic type or variations in preoperative cardiac workup would have made. Finally, the significance of the "chemical" MI is not clear. Although some suggest that even minor perioperative elevations in troponin I increase 6-month mortality 24 (not perioperative mortality), one should not necessarily conclude that the surgical procedure in question reduces one's life expectancy. Instead, it may identify patients with significant coronary disease that were not identified preoperatively by stress testing or other forms of risk stratification.
Proponents of CAS suggest several advantages to this procedure. 25 CAS avoids a general anesthetic, which may purportedly make it more feasible for patients with significant cardiopulmonary comorbidites. Angioplasty with stenting also reaches lesions that may not be surgically safely accessible, in the high cervical (above the angle of the mandible and at the skull base) and distal intracranial ICA, as well as the proximal aorto-ostial locations. In addition, cranial nerve injuries and life-threatening neck hematomas are avoided. Finally, some have suggested shorter hospital stays compared FIGURE 1. Survival curves of highrisk and low-risk patients undergoing carotid endarterectomy. At 12 months, survival was significantly worse in the high-risk group as compared with the low-risk group (91% vs. 96%, P ϭ 0.03). 30 demonstrated that when all CEAs were performed under regional anesthesia, as is almost always the case in our institution, the CAS stroke and death rate was 9.7% versus 0.9% for CEA. Some of this outcome variability certainly relates to a "learning curve" effect with fewer complications later in the operator's experience. This is reminiscent of the surgeon-volume effect seen in CEA, in which superior outcomes are seen among high-volume surgeons. 31 Furthermore, changes in the equipment used, in particular the use of "cerebral protection devices" to minimize the complications related to microemboli, may also account for these differences. Until some uniformity exists in technique, experience, and equipment, it will be difficult to assess the safety and efficacy of CAS, as well as which patients may benefit the most from CAS.
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This retrospective analysis has several limitations. Small sample size may limit our ability to document real differences among the subgroups. In addition, documentation within the medical record, both written and computer-based, can sometimes be incomplete, leaving the exact nature or timing of postoperative complications and their symptoms unclear, or failing to recognize complications in patients admitted to other institutions after CEA. Unfortunately, independent assessment of outcome by a neurologist was documented in only a minority of cases, a well-recognized limitation that may indeed underestimate the true stroke-TIA rate in our series. Furthermore, our patient population is serviced by an academic medical center with several highvolume vascular surgeons. Whether our outcomes are applicable to patients in other settings, eg, community practice or low-volume surgeons, is also not yet clear. Certainly, when comparing outcomes of CEA with CAS, controlling for these environmental differences will be important.
Overall, these results support the tenet that CEA remains the standard of care for which other procedures to prevent stroke must be measured against, regardless of medical and anatomic risks. This also challenges the definition of the "high-risk" blanket classification and suggests that until the longevity, safety, and efficacy of CAS is established, wide applicability of CAS to such "high-risk" patients should be questioned and limited to ongoing controlled clinical trials.
